Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
The Associated Press - Friday, September 1, 2000
The vaccine is the first specifically designed to combat the Clade A HIV-1 virus, the most prevalent strain in many parts of Africa.
Eighteen people volunteered to receive injections of the vaccine at Churchill Hospital in Oxford. If the tests are successful, trials will begin in Nairobi, Kenya, within six months, according to the Medical Research Council, a government-funded national research organization.
The hope is that the vaccine will stimulate the body to produce killer T-cells that will destroy HIV-infected cells fast enough to stop an infection from taking hold, the council said. If this trial is successful, it will be possible to conduct trials in volunteers who have a high risk of HIV infection, it said.
Professor Andrew McMichael, director of the council's Human Immunology Unit, said it would be three to five years before researchers would have a clear indication whether the vaccine might work. After that, it might take another five years to complete development.
The trial, announced in July at the International Conference on AIDS in Durban, South Africa, is sponsored by the International AIDS Vaccine Initiative, a global scientific organization, and supervised by the Human Immunology Unit of the Medical Research Council.
Dr. Seth Berkely, president of the International AIDS Vaccine Initiative, said four vaccines are being developed in his project. This is the first to go to human trials.
The vaccine given to the test subjects contains small fragments of DNA that are intended to boost the immune system. Since the DNA cannot be replicated, there is no danger of developing AIDS from the vaccine, the council said.
In Thailand on Thursday, researchers announced that they have reached their goal of recruiting 2,500 volunteers to test an AIDS vaccine - the first large-scale trial of such a drug in a developing country.
The AIDSVAX vaccine is produced by VaxGen Inc. (NasdaqNM:VXGN - news), a California company.
The last volunteer in the Thai trials was enrolled Aug. 24, 17 months after the first six volunteers received their first injections in late March 1999.
All the volunteers are intravenous drug users who tested HIV-negative prior to their participation. Each volunteer will receive a total of seven injections over the course of the trial.
The first test results will become available 30 months after the start of the trials.
Thailand has an estimated 1.5 million people infected with HIV, and caring for the 100,000 people with AIDS poses a high cost to the country's economy and society, said Dr. Kajit Chupanya, the project's Thai director.
-
On the Net: Oxford AIDS Vaccine Initiative, http://www.oxavi.org
000901
AP000901
Copyright © 2000 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .